BART DZIKOWSKI

Bart Dzikowski stands as a prominent figure in the life sciences investment landscape, serving as a Managing Director at the Novartis Venture Fund. In this pivotal role, he is instrumental in identifying and backing innovative companies poised to revolutionize healthcare. His strategic insights and deep industry expertise guide the fund's investments in cutting-edge therapeutics, transformative digital health solutions, and advanced platform technologies that align with Novartis's broader mission to reimagine medicine.

Dzikowski's investment philosophy centers on supporting companies with strong scientific foundations and the potential to address significant unmet medical needs. He actively seeks out opportunities across various therapeutic areas, including oncology, immunology, neuroscience, and metabolic diseases, always with an eye towards novel mechanisms of action and disruptive approaches. His portfolio reflects a commitment to pioneering science, from gene therapies and protein degradation to microbiome research and precision oncology.

Before joining the Novartis Venture Fund in 2010, Bart Dzikowski honed his expertise through a diverse and impactful career path. He gained valuable experience in the venture capital sector at MPM Capital, a leading life sciences investment firm, where he contributed to the growth of numerous biotech startups. Prior to his venture capital tenure, Dzikowski was a consultant at McKinsey & Company, advising pharmaceutical and biotechnology companies on critical strategic and operational challenges. This background provided him with a comprehensive understanding of both the scientific and business intricacies of the healthcare industry.

Academically, Dzikowski possesses a robust scientific foundation. He earned his Ph.D. in Chemistry from the University of California, Berkeley, following his undergraduate studies at the University of Chicago. Further enhancing his business acumen, he completed his Master of Business Administration (MBA) at Harvard Business School. This unique blend of scientific rigor and strategic business insight positions him as a highly effective investor capable of evaluating complex scientific propositions and guiding companies toward commercial success.

Throughout his tenure at Novartis Venture Fund, Bart Dzikowski has been a key driver behind several successful investments that have gone on to make significant impacts. His notable investments include companies like Arvinas, a leader in targeted protein degradation; IFM Therapeutics, focused on innate immunity; Vedanta Biosciences, pioneering microbiome-based therapies; Alector, developing treatments for neurodegenerative diseases; and Relay Therapeutics, advancing precision oncology through a novel drug discovery platform. Other impactful investments include Akouos, Synthekine, Palleon Pharmaceuticals, Sana Biotechnology, and Versanis Bio, each representing a strategic bet on future healthcare innovation.

Bart Dzikowski's work at the Novartis Venture Fund is not just about capital deployment; it's about fostering innovation, building strong management teams, and providing strategic guidance to help portfolio companies navigate the complex journey from scientific discovery to market success. His dedication to advancing life sciences through strategic investment makes him a pivotal figure in the biotech ecosystem.